JAK1 and cancer: In the cancer context, to determine which pathway is involved, we decided to incubate freshly isolated BMNs with SV2 supernatant and increasing doses of selected pathway inhibitors, including ruxolitinib (JAK1/2 inhibitor), stattic (STAT3 inhibitor), MLN120B (IKKβ inhibitor) and Ly294002 (PI3K inhibitor).